Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whether ...

PODD is Intuitive Surgical’s counterpart in the Health Care Equipment sector that has: 1) A lower valuation (P/OpInc) in ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

Ahead of the earnings release, Wall Street analysts expect its bottom line to grow. Analysts expect Insulet to report a ...

This was the stock's fifth consecutive day of losses.

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. See the seasonal trading ...

Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of ...

Investors interested in stocks from the Medical - Products sector have probably already heard of EssilorLuxottica Unsponsored ADR (ESLOY) and Insulet (PODD). But which of these two stocks offers value ...

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for Insulet (NasdaqGS:PODD) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 33.30% Upside As of December 21 ...